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Lysis of allogeneic and autologous melanoma cells by IL-7-induced
lymphokine-activated killer cells*
M. Bohmt, P. MoHer, U. Kalbfleisch, M. Worm, B.M. Czarnetzki & D. Schadendorf
University Hospital Rudolf Virchow, Department ofDermatology, Free University ofBerlin, Germany.
Smmuary In order to assess the potential of interleukin 7 (IL-7) as an immunotherapeutic agent in human
melanoma, we have evaluated the in vitro activity of IL-7-induced lymphokine-activated killer (LAK) cells
from patients with advanced melanoma against allogeneic and autologous melanoma cells. Peripheral blood
lymphocytes (PBLs) from 14 patients with stage III melanoma were isolated and incubated in the presence of
1,000 U ml-' IL-7 and 1 U ml-' IL-2 for comparison. LAK-ell activity was determined by a 24 h
cytotoxicity assay using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. The activity of
IL-7-induced LAK cells against two allogeneic melanoma cell lines was 32.7% (± 17.9) against SK-Mel-37 and
38.1% (± 12.5) against SK-Mel-23 at an effector-to-target (En ratio of 20:1. The activity of IL-2-induced
LAK cells was significantly higher against SK-Mel-37 (78 ± 24.6%) and against SK-Mel-23 (73.5 ± 19.7%).
IL-7 and suboptimal doses of IL-2 (10 U ml- I) were found to have a co-stimulatory on lymphocyte prolifera-
tion as well as on LAK activity. Against autologous melanoma cells, the activity of IL-7- and IL-2-induced
LAK cells did not differ significantly (55.8 ± 25.6% versus 68.7 ± 21.7% respectively). In two patients,
IL-7-induced LAK-cell activity against autologous melanoma cells exceeded even that of IL-2 significantly
(67% vs 35% and 95% vs 82%). Levels of tumour necrosis factor a (TNF-x) in the supernatants of LAK-cell
cultures generated by IL-7 were lower than those of IL-2-generated LAK-cell cultures. These results suggest
that IL-7 is a potential alternative to immunotherapy with IL-2 in terms of efficacy and possible side-effects
and encourages pilot studies with IL-7 in melanoma patients.
Immunotherapy with IL-2 with or without LAK cells has
achieved some impressive regressions in patients with
advanced melanoma who had failed on conventional therapy
(Rosenberg et al., 1985; Fletcher et al., 1987). However, the
clinical responses to this kind of therapy are infrequent and
often transient (Rosenberg et al., 1989). Furthermore, high-
dose imnunotherapy with IL-2 is associated with severe tox-
icity including pulmonary congestion, hypotension, oedema
or anuria, known as the capillary leakage syndrome (Rosen-
stein et al., 1986; Kozeny et al., 1988). These limitations of
an initially promising kind of immunotherapy have led to an
extensive search for better-tolerated treatment schedules as
well as alternative agents in immunotherapy of human
melanoma. IL-7 was originally described as a growth factor
for early B cells (Namen et al., 1988). Further characteriza-
tion revealed that IL-7 is also an important differentiation
factor for the maturation and proliferation of T lymphocytes
(Chazen et al., 1989; Londei et al., 1990). IL-7 supports the
development of cytotoxic T cells and generates LAK activity
in human PBLs against Daudi cells (Alderson et al., 1990;
St6tter & Lotze, 1991; St6tter et al., 1991). Recent data
indicate that the spectrum of cells responsive to IL-7 is
broader than originally expected and includes monocytes
(Alderson et al., 1991) and melanoma cells (Kirnbauer et al.,
1992). Therefore, IL-7 can be considered to be a multifunc-
tional cytokine acting on various cell lineages. Most recently,
human keratinocytes have been shown to secrete IL-7
(Sakimura et al., 1993), suggesting an important immuno-
regulatory role of this cytokine for dendritic T cells with in
the epidermal compartment (Matsue et al., 1993). We have
recently shown that melanoma cells from allogeneic mela-
noma cell lines can be lysed by IL-7-induced LAK cells from
healthy donors (Schadendorf et al., 1994a). IL-7-generated
LAK activity against allogeneic melanoma cell lines with
early and late differentiation markers is weaker than IL-2-
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induced LAK-cell activity. However, sparing of keratinocytes
and endothelial cells predicts that LAK cells generated by
IL-7 are more discriminative in their target cell spectrum
than IL-2-induced LAK cells (Schadendorf et al., 1994a). In
order to address the question of whether patients with
advanced malignant melanoma could benefit from immuno-
therapy with IL-7, we have examined the in vitro suscep-
tibility of allogeneic as well as autologous melanoma cells to
LAK cells (from 14 patients with metastatic melanoma)
stimulated with IL-7 or IL-2. In addition, we have evaluated
the comparative concentrations of TNF-a in the supernatants
of LAK-ell cultures generated by IL-7 or IL-2 since secon-
darily induced cytokines such as TNF-x are thought to play
a key role in the development of side-effects during
immunotherapy with IL-2 (Siegel & Puri. 1991).
Material and methods
Cvtokines
Human recombinant IL-7 was provided by Immunex (Seat-
tle, WA, USA) with a specific activity of 4.7 x 10' U mg-'
and 3.9 endotoxin units per ng of protein. The specific
activity was determined with a bioassay that employs the
IL-7-dependent IxN/Lb pre-B-cell line (Namen et al., 1988).
Human recombinant IL-2 was purchased from Boehringer
(Mannheim, Germany) and had a specific activity of
2 x 106 U mg-' and fewer than 100 endotoxin units per ng.
Cell culture ofmelanoma cell lines
The human melanoma cell lines SK-Mel-37 and SK-Mel-23
were grown as previously described (Schadendorf et al.,
1994b). Both cell lines were established several years ago at
the Memorial Sloan Kettering Cancer Center from metastatic
lesions derived from patients with malignant melanoma.
Their differentiation markers have been characterised exten-
sively (Worm et al., 1993).
Preparation ofautologous melanoma cells
Tumour specimens were collected from patients with
advanced melanoma undergoing procedures as a part of
either diagnostic work-up or treatment of their disease. Fresh
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melanoma cells from tumour specimens from lymph nodes,
cutis or subcutis were prepared as described previously
(Schadendorf et al., 1994b). For testing, passages 2-5 were
used. Parallel cytospins of the tumour cells were done, and it
was confirmed by immunocytochemistry that >95% were
-100 positive.
LAK-cell generationfrom patients with melanoma
Peripheral blood mononuclear cells (PBMCs) were obtained
from 14 patients with stage III melanoma (age 32-89, equal
sex ratio) by Ficoll-Hypaque centrifugation. Any form of
chemotherapy, immunotherapy or hormone therapy had to
be discontinued 6 weeks before blood collection. After
removal of the adherent monocytes by incubating the
PBMCs on plastic plates for 1 h at 37C, the PBLs were
decanted and either cryopreserved or immediately processed
for the generation of LAK cells (Grimm et al., 1982;
Schadendorf et al., 1994b). In short, PBLs were incubated at
a density of 2 x 106 cells ml-' in RPMI-1640 supplemented
with glutamine, fetal calf serum and antibiotics as mentioned
above, and 1,000 U ml1' IL-7 or 100 U ml1' IL-2. One thou-
sand units of IL-7 represents 0.1 mg and 100 U of IL-2
represents 0.033 mg. The cells were incubated in 25 cm2 flasks
(Greiner, Frickenhausen, Germany) in an upright position
for 4 days in 5% carbon dioxide at 3rC. On day 4, LAK-
cell concentration was determined by haemocytometer counts
of cells excluding 0.18% trypan blue dye.
Ctotoxicitiv assay
LAK-cell activity was determined with a 24 h tetrazolium-
based colorimetric assay originally described by Mosman
(1983). The measured absorbance is proportional to the
number of viable cells. Modified as a cytotoxicity assay for
the quantification of anti-tumour effects mediated by LAK
cells, this test has been found to compare favourably with the
5'Cr-release assay in terms of sensitivity and reproducibility,
particularly if long-term cytotoxicity is to be measured (Heo
et al., 1990). The MTT assay was performed as follows.
Melanoma cells were brought to single-cell suspension by
incubation with 0.25% trypsin-EDTA solution (Seromed,
Berlin, Germany). Cell concentration and viability were
determined by haemocytometer counts excluding 0.18%
trypan blue dye. Melanoma cells were plated at a density of
1 x 10'cells per well in 96-well flat-bottomed tissue culture
microtitre plates (Greiner) 20 h prior to the addition of LAK
cells. LAK cells were added at different E/T ratios ranging
from 20:1 to 2.5:1. Quintuplicates were used for every E/T
ratio. After incubation for 24 h, non-adherent cells were
removed by performing three consecutive washings with
unsupplemented medium. To ensure lethal damage of
detached cells, recultivation of detached cells was performed,
which failed in all experiments. MTT (Sigma, Deisenhofen,
Germany) at a final concentration of 0.5 mgml-' was added
to each well and plates were incubated for 4 h at 3TC.
Absorbance was read at a wavelength of 540 nm on a scan-
ning multiwell spectrophotometer (Titertek Multiscan MCC/
340, Meckenheim, Germany). The percentage of lysis was
determined as:
A - (B -C) Lysis (%) = x x 100 A
where A is the-mean optical density of 1 x 10' melanoma
cells without addition of LAK cells, B is the mean experi-
mental absorbance of adherent melanoma cells remaining in
the wells after washing and C represents a correction factor
for 'sticky' LAK cells that remain in the wells after washing
and was obtained by plating different numbers of LAK cells
in the wells without melanoma cells added.
Determination of TNF-a
TNF-a levels in the supernatants of LAK-cell cultures were
measured by a quantitative immunoenzymometric kit (R&D
Systems, Quantikine, Minneapolis. USA). The sensitivity was
4.8 pgml' as indicated by the manufacturer.
Statistical analysis
The statistical significance of the data obtained from the
cytoxicity assays and TNF-t levels was calculated using a
modified Wilcoxon signed-rank test (Conover & Iman, 1981).
The procedure involves conversion of the observations to
rank order and subsequent calculation of the t-statistic by
using ranks instead of the original observations.
Resuts
IL-7-induced LAK cellsfrompatients with melanoma are
cytotoxic against allogeneic melanoma cells
IL-7-induced LAK activity against SK-Mel-37 and SK-
Mel-23 was found to be higher than the cytotoxicity of
unstimulated lymphocytes in 11 of 14 patients. The mean
cytoxicity of LAK cells generated by IL-7 was 32.7%
(± 17.9) against SK-Mel-37 and 38.1% (± 12.5) against SK-
Mel-23 at an E/T ratio of 20:1 (Figure 1). Induction of
IL-7-induced LAK activity was statistically significant com-
pared with unstimulated lymphocytes (P = 0.05). In three out
of 14 patients, IL-7-induced LAK activity against either SK-
Mel-37 or SK-Mel-23 did not exceed that of unstimulated
PBLs. However, the reduced IL-7-induced LAK activity in
these patients did not correlate with age, sex or tumour
burden. IL-7-induced LAK activity was also found to be
proportional to the E/T ratio (Figure 2, as paradigmatically
shown for one patient).
IL-2-induced LAK activity higher than activity of un-
stimulated PBLs was generated in 13 out of 14 patients and
was higher than LAK activity generated by IL-7 in all
patients (Figure 1). The mean cytotoxicity of IL-2-generated
LAK cells was 78% (± 24.6) against SK-Mel-37 and 73.5%
(± 19.7) against SK-Mel-23 at an E/T ratio of 20:1. No
significant differences were found regarding the susceptibility
of the highly differentiated melanoma cell line SK-Mel-23
and the lesser differentiated cell line SK-Mel-37 to either
IL-7- or IL-2-induced LAK cells.
IL-7 induces LAKactivity against autologous melanoma cells
LAK cells from seven patients were available for assessing
their autologous LAK activity. IL-7-induced LAK cells from
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Figwe 1 In vitro LAK activity of IL-7-induced ( ) and
IL-2-induced ( M ) LAK cells derived from 14 patients with
advanced melanoma. The percentage Iysis of two allogeneic
melanoma ceUs lines (SK-Mel-37 and SK-Mel-23) which differ in
their differentiation features (Worm et al., 1993) is depicted at an
ET ratio of 20:1. Unstimulated PBLs ( = ) were grown in
complete medium containing 10% fetal calf serum and were used
as controls (P = 0.05). The mean percentage lysis and the stan-
dard deviation are given. All experiments were performed in
quintuplicate and were repeated at least twice.
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all patients were found to lyse autologous melanoma cells to
a variable degree (Figure 3 and Table I, as shown for five
patients). The mean cytotoxicity of LAK cells generated by
IL-7 was 55.8% (± 25.6) and by IL-2 68.7% (± 21.7), at an
E/T ratio of 20:1. Interestingly, IL-7-induced LAK activity
in PBLs from two patients exceeded IL-2-induced LAK
activity by 32% and 13% (patients K.U. and S.U. in Figure
3). LAK activity of IL-2- and IL-7-induced LAK cells
directed against autologous melanoma cells was also found
to be proportional to the EIT ratio (data not shown).
Comparison between allogeneic andautologous LAKactivity
derivedfrom melanoma patients
To exclude intraindividual variations in LAK activity when
blood samples were taken and processed at different times,
PBLs from five patients were isolated, and the cytotoxicity of
IL-7- and IL-2-induced LAK cells was measured simul-
taneously against allogeneic and autologous melanoma cells
(Table I). No consistent pattern of LAK activity against
allogeneic and autologous melanoma cells could be found. In
patient K.I., the IL-7-induced LAK activity against auto-
logous melanoma cells was almost identical to the activity of
unstimulated PBLs, and IL-2-induced autologous LAK
activity was also in the lower range compared with other
patients shown in Table I and Figure 3. In contrast,
0- 0-
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allogeneic LAK activity generated by IL-2 was high in this
particular patient.
IL-7-induced LAK cellsproduce less TNF-a than LAK cells
generated by IL-2
Figure 4 shows the concentration of TNF-u in the super-
natants of the LAK-cell cultures generated by IL-7 or IL-2 in
comparison with unstimulated PBLs. The median of the
concentration of TNF-a in the supernatants of IL-2-induced
LAK cells was 325 pgml-' (range 68-2,050 pg ml-') in con-
trast to 147 pgml-' (range 15-1,055pgml-') in the super-
natants of IL-7-induced LAK-cell cultures (P<0.01). No
differences between TNF-1 levels in supernatants of IL-7-
induced PBLs was noted compared with levels of un-
stimulated PBLs (median ll9pgml-', range 15-392pg
ml-'). No correlation was found between IL-2- or IL-7-
induced TNF-x and the individual LAK activity against
allogeneic or autologous melanoma cells.
Effects ofIL-2 and IL-7 on lymphocyteproliferation and LAK
activity
As demonstrated in Table II, IL-2 (lOUml-' and 1,000 U
ml-') as well as IL-7 had a proliferative effect on PBLs
compared with unstimulated lymphocytes (P<0.01). IL-7
-
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Fge 2 Lysis of SK-Mel-37 by IL-7- (U) and IL-2-induced
(0) LAK cells and unstimulated PBLs (0) derived from patient
S.U. Different E/T ratios ranging from 20:1 to 2.5:1 were used to
assess the LAK activity.
Patients
Fugwe 3 LAK activity of autologous melanoma cells by IL-7-
induced (_) and IL-2-induced ( ) LAK cells in com-
parison with unstimulated PBLs. ( L ) Lympocytes from seven
patients with stage III melanoma were examined (W.E., K.I.,
G.R., KIU., S.U., H.O., E.W.). All experiments were performed
in quintuplicate and were repeated at least twice.
TableI ComparativecytotoxicityofLAKcells generated by IL-7 and IL-2against SK-Mel-37
and SK-Mel-23 andautologousmelanomacells. LAK-cellactivityinpercentlysisofPBLsfrom
fivepatientsisdepictedatanE/Tratioof20:1.ThesamefractionofPBLsfromeverypatientwas
used to evaluate the alloreactive and autologous LAK cell activity simultaneously. All
experiments were performed in quintuplicate and have been repeated twice
Effector cells
Patient G.R. Unstimulated lymphocytes
LAK (IL-2)
LAK (IL-7)
Patient S.U. Unstimulated lymphoytes
LAK (IL-2)
LAK (IL-7)
Patient K.I. Unstimulated lymphocytes
LAK (IL-2)
LAK (IL-7)
Patient K.U. Unstimulated lymphocytes
LAK (IL-2)
LAK (IL-7)
Patient E.W. Unstimulated lymphocytes
LAK (IL-2)
LAK (IL-7)
Lysis (%)
Autologous SK-Mel-37
11 31
53 69
39 38
32
82
95
36
55
39
24
35
67
15
76
11
49
26
32
94
43
21
47
39
17
83
NE
NE, not evaluable.
SK-Mel-23
18
57
34
33
53
58
28
90
29
32
46
NE
27
50
30
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Table II Effect ofthe combination ofIL-2 and IL-7 on lymphocyte proliferation (a) and LAK activity (b). (a) Lymphocyte proliferation
was determined in four independent experiments in quadruplicate by MTT test (s.d.<10%). All values represent the ratio of
lymphokine-stimulated tounstimulated PBLsafter6days. LAKactivitywasdetermined in aparalkl setofexperiments. (b) LAKactivityis
givenaspercentlysisofSK-Mel-23 cellsata20:1 E/Tratio(meanoftendifferentdonorsdeterminedinquadruplicate, s.d. <10%). Similar
results were obtained with four different donors on SK-Mel-37 cells (data not shown)
Unstimdated PBLs IL-2 (10) IL-2 (1,000) IL-7 (1,000) IL-7 (1,000)/IL-2 (10) IL-7 (1,000)/IL-2 (1,000)
(a) Lymphocyte proliferation
Median 1.0 1.17 1.56 1.50 1.56 1.71
Range 1.0 1.00-1.35 1.13-1.76 1.04-1.80 1.03-1.81 1.21-2.17
(b) Cytotoxicity
Mean 33.9 49.9 80.7 ± 43.3 55.7 78.3
s.d. ±10.9 ±11.1 + 11.2 ±5.8 ±13.4 ±10.1
10,000o-
E
z
1,000 -
100 -
in lU
0
0 9
Unstimulated
PBLs
0
0
0
0
0 .
0
IL-2 IL-7
Fugwe 4 TNF-a levels in the supernatants of LAK cell cultures
generated by IL-7 and IL-2 compared with unstimulated PBLs
measured by an immunoenzymometric assay. Supernatants from
LAK cell cultures derived from six patients. (0, G.R.; *, E.W.;
0, K.I.; O, W.E.; U, K.U.; 0, S.U.) were examined for their
concentration of TNF-a.
(1,000 U ml') and suboptimal concentrations of IL-2 (10 U
ml-') cooperate in their capacity to promote lymphocyte
proliferation compared with IL-2 (10 U ml-') (P<0.05)
(Table Ila). As can be seen in Table lIb, cytotoxicity in-
creased dose dependently with IL-2 concentration. However,
LAK activity of IL-2 (10 U ml-') was significant lower than
the combination of suboptimal IL-2 (10 U ml-') and IL-7
(1,000 U ml') (P<0.05).
DEi
IL-7 has recently been found to induce LAK activity in PBLs
derived from healthy donors against a variety of target cells,
including haematological cell lines (A erson et al., 1990;
St6tter & Lotze, 1991; St6tter et al., 1991) and allogeneic
melanoma cell lines (Schadendorf et al., 1994a). In our
previous experiments, IL-7-induced LAK cells from healthy
donors lysed SK-Mel-37 and SK-Mel-23 at a mean percen-
tage of 41% (± 12%) (Schadendorf et al., 1994a). We have
amplified these findings by analysing the IL-7-induced LAK
activity of patients with melanoma against allogeneic and,
more importantly, autologous melanoma cells.
The mean cytoxicity of IL-7-induced LAK cells directed
against SK-Mel-37 and SK-Mel-23 (36.5 ± 17.5%) is only
slightly lower and not significantly different from LAK cells
derived from healthy donors and patients with metastatic
melanoma. It remains unclear whether the reduced allogeneic
IL-7-induced LAK activity in three of 14 patients can be
attributed to a general or specific immunosuppression or
whether it reflects normal interindividual variations in the
inducibility of LAK cells. Reduced natural killer (NK)-cell
activity has been reported in patients with advanced cancer
(Morikawa et al., 1989; Villa et al., 1991). On the other hand,
we found striking interindividual differences in the degree of
IL-7-induced LAK cell-activity even among healthy volun-
teers (Schadendorf et al., 1994a).
More important than alloreactive LAK activity of IL-7-
induced LAK cells from patients with melanoma seems to be
the fact that IL-7 enables PBLs to kill autologous melanoma
cells. Bearing in mind that LAK activity induced by IL-7 acts
in large part independently of IL-2 (St6tter et al., 1991a), this
cytokine seems a possible alternative to IL-2 and a good
candidate for future immunotherapy of patients with
advanced melanoma. IL-7-induced LAK activity in PBLs
from two patients even exceeded that of IL-2 by 32% and
13%. These data extend the findings of Jicha et al. (1992),
who showed a similar cytoxicity of IL-7- and IL-2-generated
draining lymph node-derived lymphocytes against syngeneic
autologous MCA tumour.
The effector cell phenotype of IL-7-induced LAK cells was
studied by Naume et al. (1991) and shown to be of the
CD56+CD3- phenotype. Furthermore, Smyth et al. (1991)
demonstrated that large granular lymphocytes (LGLs) (main-
ly CD56+CD3- phenotype) stimulated by IL-7 had LAK
activity and secreted IFN-r, although in lower quantities
than IL-2.
Differences in LAK activity between allogeneic and
autologous cells have been reported (Foa et al., 1990). High
alloreactive LAK activity coupled with low LAK activity
directed against autologous melanoma cells may be related in
part to clonal expansion of alloreactive MHC-restricted NK
cells, as recently postulated (Moretta et al., 1992). Differences
in the responsiveness to IL-2 and IL-7 activation of NK cells
could be another reason. However, other mechanisms, such
as the induction ofco-stimulatory signals, including adhesion
molecules, as described recently (Altomonte et al., 1993; Piali
et al., 1993; Poggi et al., 1993; Vyth-Dreese et al., 1993), have
to be considered. Such a mechanism might help to explain
the high autologous cytotoxicity generated by IL-7 observed
in 2/5 of our patients (K.I. and S.U.). Specific cytotoxic T
lymphocytes (CTILs) are most likely not involved, since the
precursor frequency for tumour-specific CTLs ranges around
1:20,000 and effective clonal proliferation of CTLs needs
between 2 and 4 weeks (Coulie et al., 1992).
The finding that IL-7-induced LAK cells produce less
TNF-a than IL-2-induced LAK cells is in accordance with
data from others who have shown a 50-fold lower amount of
that cytoline in the supernatants of IL-7-stimulated
immunomagnetically purified CD56+ lymphocytes (Naume et
al., 1991). Since TNF-a as well as IFN-r is thought to be
involved in the pathogenesis of the capillary leakage syn-
drome during high-dose immunotherapy with IL-2 (Siegel &
Puri, 1991), lower in vivo induction of these cytokines during
immunotherapy with IL-7 is likely to cause fewer side-effects
than IL-2.
Taken together, our previous (Schadendorf et al., 1994a)
and present findings suggest that
1. IL-7-induced LAK cells from patients with melanoma
lyse allogeneic melanoma cell lines to a variable degree.
2. Suboptimal concentrations of IL-2 and IL-7 act co-
operatively in expanding PBLs as well as in generating
LAK activity, which is in line with results reported by
Smyth et al. (1991).
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3. Autologous melanoma cells are susceptible to lysis by
LAK cells generated by IL-7.
4. Lysis of autologous melanoma cells by IL-7-induced
LAK cells can exceed IL-2-induced LAK-cll activity in
at least some patients.
5. In addition to the more discriminative killing spectrum of
IL-7-induced LAK cells in companson with IL-2-induced
LAK cells, which lyse even endothelial cells and
keratinocytes (Schadendorf et al., 1994a), lower induction
of cytokines such as TNF-a upon IL-7 application may
minimise severe side-effects that are commonly seen dur-
ing high-dose immunotherapy with IL-2.
Our findings are encouraging for clinical pilot studies on
patients with advanced melanoma using IL-7 either alone or
in combination with IL-2.
Abbrevations: IL-7, interleukin 7: IL-2. interleukin 2; LAK.
lymphokine-activated killer, PBL, peripheral blood lymphocyte;
MTT. 3-[4.5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide:
NK. natural killer: TNF. tumour necrosis factor, IFN. interferon.
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